Claire Gibrat

ORCID: 0000-0003-0416-1525
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Parkinson's Disease Mechanisms and Treatments
  • Nuclear Receptors and Signaling
  • Coronary Interventions and Diagnostics
  • Vascular Procedures and Complications
  • Nerve injury and regeneration
  • Adenosine and Purinergic Signaling
  • Neurological diseases and metabolism
  • Acute Myocardial Infarction Research
  • RNA regulation and disease
  • Cardiac Imaging and Diagnostics
  • Antiplatelet Therapy and Cardiovascular Diseases
  • Cardiac pacing and defibrillation studies
  • Porphyrin Metabolism and Disorders
  • Diet and metabolism studies
  • Neuroinflammation and Neurodegeneration Mechanisms
  • Adipose Tissue and Metabolism
  • Genetic Neurodegenerative Diseases
  • Biomedical Research and Pathophysiology
  • Plant-based Medicinal Research
  • Yersinia bacterium, plague, ectoparasites research
  • Conducting polymers and applications
  • Fatty Acid Research and Health
  • Cardiac and Coronary Surgery Techniques
  • Cardiac Arrhythmias and Treatments
  • Amino Acid Enzymes and Metabolism

Université Laval
2015-2018

McGill University Health Centre
2016

Montreal Heart Institute
2016

Centre hospitalier universitaire de Québec
2015

Centre hospitalier de l'Université Laval
2009-2011

Wilfrid Laurier University
2009-2010

Abstract Animal models are invaluable tools to study neurodegenerative disorders but a general consensus on the most accurate rodent model of Parkinson’s disease has not been reached. Here, we examined how different methods MPTP administration influence degeneration dopaminergic (DA) system. Adult male C57BL/6 mice were treated with same cumulative dose following four distinct procedures: (i) subacute i.p. injections; (ii) 28‐day chronic s.c. infusion; (iii) and (iv) 14‐day infusion....

10.1111/j.1471-4159.2009.06072.x article EN Journal of Neurochemistry 2009-03-30

Background— The prevalence of native coronary chronic total occlusions (CTOs) after artery bypass grafts (CABGs) is higher than in non-CABG population. We examined outcomes CTO percutaneous intervention (PCI) post-CABG versus without CABG. Then, we looked at feasibility and retrograde PCI via patent or occluded saphenous vein graft. Methods Results— compared patient procedural characteristics 470 cases treated from January 2010 to December 2015 depending on history assessed major adverse...

10.1161/circinterventions.115.003515 article EN Circulation Cardiovascular Interventions 2016-07-01

Septal surfing and distal tip injections are two techniques used for septal crossing in retrograde chronic total occlusion (CTO) percutaneous coronary interventions (PCI). The aim of this study was to examine the first time safety feasibility technique.Among 470 consecutive CTO PCIs performed Quebec hybrid PCI program between January 2010 December 2015, 240 (51%) involved a attempt. In subgroup, we evaluated whether Werner collateral channel (CC) classification, location, tortuosity, number...

10.4244/eij-d-16-00650 article EN EuroIntervention 2017-02-01

J. Neurochem. (2010) 114 , 1651–1658. Abstract Cystamine has shown significant neuroprotective properties in preclinical studies of Parkinson’s disease (PD) and Huntington’s (HD). Cysteamine, its FDA‐approved reduced form, is scheduled to be tested for clinical efficacy HD patients. Here, we studied the key cystamine metabolites, namely cysteamine, hypotaurine taurine, as well cysteine, order identify which one more distinctively responsible action cystamine. After a single administration...

10.1111/j.1471-4159.2010.06874.x article EN Journal of Neurochemistry 2010-06-21

Abstract Background Mounting evidence supports a significant role of inflammation in Parkinson's disease (PD) pathophysiology, with several inflammatory pathways being suggested as playing the dopaminergic degeneration seen humans and animal models disease. These include tumor necrosis factor, prostaglandins oxidative-related stress components. However, innate immunity has not been established PD. Methods Based on fact that myeloid differentiation primary response gene (88) (MyD88) is most...

10.1186/1742-2094-8-137 article EN cc-by Journal of Neuroinflammation 2011-10-11

Abstract Objectives We examined the incidence of periprocedural cardiac enzyme rise (PCER) [troponin T (TnT) or high‐sensivity (hs)TnT >5× upper limit normal (ULN)] and myocardial infarction (PMI), predictors PCER impact on longer‐term major adverse events (MACE) following hybrid chronic total occlusion (CTO) percutaneous coronary intervention (PCI). Background PMI after CTO PCI, risk factors for its MACE are not fully understood. Methods Among 469 PCI cases performed between 01/2010...

10.1002/ccd.27545 article EN Catheterization and Cardiovascular Interventions 2018-02-26
Coming Soon ...